MCID: HPT001
MIFTS: 71

Hepatitis C

Categories: Infectious diseases, Liver diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases, Immune diseases, Endocrine diseases

Aliases & Classifications for Hepatitis C

MalaCards integrated aliases for Hepatitis C:

Name: Hepatitis C 12 76 55 43 44 15 73
Hepatitis C, Chronic 44 73
Hepatitis C Infection 12
Chronic Hepatitis C 12
Hepatitis Nona Nonb 12
Hepatitis C Chronic 55
Viral Hepatitis C 12
Nanbh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1883
ICD10 33 B19.2 B19.20
ICD9CM 35 070.7
NCIt 50 C3098

Summaries for Hepatitis C

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis C, is caused by the hepatitis C virus (HCV). It usually spreads through contact with infected blood. It can also spread through sex with an infected person and from mother to baby during childbirth. Most people who are infected with hepatitis C don't have any symptoms for years. If you do get symptoms, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. A blood test can tell if you have it. Usually, hepatitis C does not get better by itself. The infection can last a lifetime and may lead to cirrhosis (scarring of the liver) or liver cancer. Medicines sometimes help, but side effects can be a problem. Serious cases may need a liver transplant. There is no vaccine for HCV. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis C, also known as hepatitis c, chronic, is related to hepatitis c virus and cryoglobulinemia, familial mixed, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis C is MIR122 (MicroRNA 122
Liver-specific miR-122 has been implicated in the control of hepatitis C virus (HCV) RNA replication and its response to interferon (IFN) in human hepatoma cells. Liver biopsies from subjects with chronic hepatitis C (CHC) undergoing IFN therapy revealed no correlation of miR-122 expression with viral load and markedly decreased pretreatment miR-122 levels in subjects who had no virological response during later IFN therapy; other investigated miRNAs showed only limited changes. These data have implications for the prospect of targeting miRNAs for CHC therapy.), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Miconazole and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and testes, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and hematopoietic system

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis C virus, which is transmitted by blood from an infected person enters the body of an uninfected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 76 Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the... more...

Related Diseases for Hepatitis C

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 562)
# Related Disease Score Top Affiliating Genes
1 hepatitis c virus 33.1 CD81 CLDN1 CLDN6 DDX58 GPT IFNG
2 cryoglobulinemia, familial mixed 31.8 IFNA1 IFNA2
3 viral hepatitis 31.7 GPT IFNA1 IFNA2
4 hepatitis b 31.4 GPT IFNA1 IFNA2 IFNAR2 IFNG
5 oral erosive lichen 30.9 IFNA1 IFNB1
6 hepatitis 30.8 CD81 CLDN1 CLDN6 DDX58 GPT IFNA1
7 west nile virus 30.5 DDX58 IFNA1 IRF3
8 stomatitis 30.5 DDX58 IFNA1 IFNA2 LDLR
9 hepatitis e 30.5 DDX58 GPT IFNG
10 vaccinia 30.2 IFNA1 IFNB1 IRF3 IRF7
11 severe acute respiratory syndrome 30.0 IFNA1 IFNB1 IFNG IRF3
12 kaposi sarcoma 29.7 IFNA1 IFNA2 IFNB1 IRF3 IRF7
13 measles 29.5 DDX58 IFNA1 IFNAR2 IFNB1 IFNG
14 influenza 29.3 DDX58 IFNA1 IFNB1 IFNG IRF3 IRF7
15 renal cell carcinoma, nonpapillary 29.1 HOTAIR IFNA1 IFNA2 IFNG
16 chronic end-stage hepatitis c 12.0
17 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.0
18 hepatocellular carcinoma 11.5
19 liver disease 11.3
20 porphyria cutanea tarda 11.3
21 fatty liver disease 11.2
22 fibrillary glomerulonephritis 11.2
23 linear lichen planus 11.2
24 immunotactoid glomerulopathy 11.2
25 immunotactoid or fibrillary glomerulopathy 11.2
26 lymphomatoid granulomatosis 10.9 IFNA1 IFNA2
27 pars planitis 10.9
28 intermediate uveitis 10.9
29 gianotti crosti syndrome 10.9
30 papular mucinosis 10.9
31 squamous papillomatosis 10.8 IFNA1 IFNA2
32 pediatric lymphoma 10.7 CD81 IRF3 IRF7
33 eczema herpeticum 10.7 IFNG IRF3 IRF7
34 cryoglobulinemia 10.7
35 la crosse encephalitis 10.6 DDX58 IFNB1 IRF3
36 mouth disease 10.6 IFNA1 IFNG IRF3 JAK1
37 relapsing-remitting multiple sclerosis 10.6 IFNA1 IFNB1 IFNG
38 septicemic plague 10.5 IFNAR1 IFNB1 IRF3
39 herpes simplex 10.4 DDX58 IFNA1 IFNB1 IRF3
40 demyelinating disease 10.4 IFNA1 IFNB1 IFNG
41 glomerulonephritis 10.4
42 lymphoma 10.4
43 porphyria 10.4
44 diabetes mellitus, noninsulin-dependent 10.4
45 mucinoses 10.4 IFNB1 IFNG
46 liver cirrhosis 10.3
47 membranoproliferative glomerulonephritis 10.3
48 newcastle disease 10.3 DDX58 IFNA1 IFNB1 IRF3 IRF7
49 thyroiditis 10.3
50 vasculitis 10.3

Graphical network of the top 20 diseases related to Hepatitis C:



Diseases related to Hepatitis C

Symptoms & Phenotypes for Hepatitis C

Symptoms:

12
  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • clay-colored bowel movements
  • joint pain
  • jaundice

GenomeRNAi Phenotypes related to Hepatitis C according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.02 CD81 CLDN1 GPT IRF3 IRF7

MGI Mouse Phenotypes related to Hepatitis C:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 IFNAR2 IFNB1 IFNG IRF7 JAK1 LDLR
2 homeostasis/metabolism MP:0005376 9.73 IFNAR2 IFNB1 IFNG IRF3 IRF7 JAK1
3 immune system MP:0005387 9.36 IFNAR2 IFNB1 IFNG IRF3 IRF7 JAK1

Drugs & Therapeutics for Hepatitis C

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 580)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
3
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
4
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
5
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
9
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
10
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
11
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 143491-57-0 60877
12
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
13
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
14
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
15
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
16
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
17
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
18
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
19
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
20
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
21
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
22
Insulin Glargine Approved Phase 4 160337-95-1
23
Insulin glulisine Approved Phase 4 207748-29-6
24
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 23994
25
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 1
26
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 923604-59-5 66576988
27
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
28
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128794-94-5 5281078
29
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
30
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
31
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 154598-52-4 64139
32
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 134678-17-4 60825
33
Zidovudine Approved Phase 4,Phase 1,Phase 2 30516-87-1 35370
34
Interferon alfacon-1 Approved, Investigational Phase 4,Phase 3,Phase 2 118390-30-0 9554198
35
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
36
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152923-56-3, 179045-86-4
37
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 561-27-3 5462328
38
Nevirapine Approved Phase 4 129618-40-2 4463
39
Rifaximin Approved, Investigational Phase 4,Phase 2,Not Applicable 80621-81-4 6436173
40
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
41
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
42
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
43
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
44
Losartan Approved Phase 4 114798-26-4 3961
45
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
46
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
47
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
48
Nelfinavir Approved Phase 4 159989-64-7 64143
49
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
50
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 2273)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
3 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
4 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
5 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
6 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
7 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
8 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
9 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
10 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
11 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
12 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
13 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
14 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
15 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
16 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
17 Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
18 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
19 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
20 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
21 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
22 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
23 Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents. Unknown status NCT02802280 Phase 4
24 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
25 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
26 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
27 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
28 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
29 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
30 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
31 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
32 Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel) Unknown status NCT01230931 Phase 4
33 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
34 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
35 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
36 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
37 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4 Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
38 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World Completed NCT02964091 Phase 4 sofosbuvir/ledipasvir
39 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4 cyclosporin (Neoral);tacrolimus (Prograf)
40 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
41 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C Completed NCT00917358 Phase 4 Pegylated interferon alfa-2a
42 A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 Completed NCT01258101 Phase 4 peginterferon alfa-2a [Pegasys];peginterferon alfa-2a [Pegasys];ribavirin;ribavirin
43 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
44 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
45 A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C Completed NCT01675427 Phase 4
46 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
47 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
48 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
49 Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection Completed NCT02377856 Phase 4 pegylated interferon alpha 2a, ribavirin
50 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed NCT02781649 Phase 4 Zepatier;Ribavirin;Sofosbuvir

Search NIH Clinical Center for Hepatitis C

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hepatitis c

Genetic Tests for Hepatitis C

Anatomical Context for Hepatitis C

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis C:

19
Liver

MalaCards organs/tissues related to Hepatitis C:

41
Liver, Testes, Kidney, T Cells, B Cells, Skin, Thyroid

Publications for Hepatitis C

Articles related to Hepatitis C:

(show top 50) (show all 7518)
# Title Authors Year
1
Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. ( 29751763 )
2018
2
Hepatitis C virus infection in children in the era of direct-acting antiviral. ( 29962813 )
2018
3
Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. ( 29429421 )
2018
4
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. ( 29757684 )
2018
5
Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. ( 29972246 )
2018
6
Hepatitis C screening in patients with oral lichen planus. ( 29971956 )
2018
7
Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. ( 29248968 )
2018
8
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. ( 29235977 )
2018
9
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. ( 29438195 )
2018
10
Hepatitis C virus infection and risk of osteoporotic fracture: A systematic review and meta-analysis. ( 29322660 )
2018
11
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). ( 29977962 )
2018
12
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. ( 29971486 )
2018
13
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with I^-Thalassemia Major. ( 29743790 )
2018
14
HIV and hepatitis C virus infections in Quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015. ( 29981093 )
2018
15
Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center. ( 29962673 )
2018
16
Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. ( 29443378 )
2018
17
Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. ( 29446443 )
2018
18
Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection. ( 29974665 )
2018
19
Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C. ( 29399747 )
2018
20
Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients. ( 29290175 )
2018
21
Psychiatric and functional neuroimaging abnormalities in chronic hepatitis C virus patients: Is vasculitis a contributing factor? ( 29935864 )
2018
22
Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )
2018
23
Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. ( 29438397 )
2018
24
Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. ( 29557805 )
2018
25
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. ( 29271782 )
2018
26
Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. ( 29975243 )
2018
27
microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. ( 29973597 )
2018
28
Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. ( 29022122 )
2018
29
Cerebral Malaria in a Patient with HIV, Hepatitis B, and Hepatitis C. ( 29974024 )
2018
30
Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. ( 29981176 )
2018
31
Genetic variations in toll-like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression. ( 28752959 )
2018
32
Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. ( 29959866 )
2018
33
Mother-to-child transmission of hepatitis C virus. ( 29968442 )
2018
34
Training in emerging advances in chronic hepatitis C infection in Pakistan: the Teach - Pak project. ( 29445310 )
2018
35
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. ( 29961309 )
2018
36
Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. ( 29437963 )
2018
37
Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried-Blood Spot Samples. ( 29959023 )
2018
38
Long-term familial Mediterranean fever remission on successful hepatitis C virus treatment in a patient not responding to colchicine: a case report. ( 29773081 )
2018
39
Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients. ( 29737561 )
2018
40
Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations? Authors' reply. ( 29446133 )
2018
41
Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. ( 29954253 )
2018
42
Coexistent Ipsilateral Internal Carotid Artery Occlusion and Cerebral Venous Thrombosis in Hepatitis C. ( 29349091 )
2018
43
The Role of Aging, Drug Dependence, and Hepatitis C Comorbidity in Alcoholism Cortical Compromise. ( 29541774 )
2018
44
In vitro basal T-cell proliferation among asymptomatic Human T cell Leukemia Virus type 1 patients co-infected with hepatitis C and/or Human Immunodeficiency Virus type 1. ( 29499169 )
2018
45
The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. ( 29411135 )
2018
46
Atypical generalized morphea-like scleroderma occurring in a patient exposed to organic solvents and having chronic hepatitis C virus infection. ( 29451196 )
2018
47
Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model. ( 29437969 )
2018
48
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? ( 29443655 )
2018
49
The next wave of hepatitis C virus: The epidemic of intravenous drug use. ( 29427493 )
2018
50
Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C. ( 29846860 )
2018

Variations for Hepatitis C

Expression for Hepatitis C

Search GEO for disease gene expression data for Hepatitis C.

Pathways for Hepatitis C

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 CD81 DDX58 IFNA1 IFNA2 IFNAR1 IFNAR2
2
Show member pathways
13.42 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IFNG
3
Show member pathways
13.3 DDX58 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
4
Show member pathways
12.98 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IFNG
5
Show member pathways
12.95 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IRF3
6 12.79 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNG JAK1
7
Show member pathways
12.78 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNG
8
Show member pathways
12.73 DDX58 IFNA1 IFNA2 IFNB1 IFNG IRF3
9
Show member pathways
12.71 DDX58 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
10 12.56 DDX58 IFNA1 IFNG IRF3 IRF7 JAK1
11
Show member pathways
12.54 DDX58 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
12
Show member pathways
12.51 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IFNG
13
Show member pathways
12.5 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IFNG
14
Show member pathways
12.35 DDX58 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
15
Show member pathways
12.31 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IFNG
16 12.23 IFNA1 IFNA2 IFNB1 IFNG JAK1
17 12.22 DDX58 IFNG IRF3 JAK1
18
Show member pathways
12.21 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IFNG
19 12.15 IFNA1 IFNA2 IFNB1 IRF3 IRF7
20 12.04 IFNAR1 IFNAR2 IFNB1 IFNG JAK1
21 11.92 CD81 CLDN1 CLDN6 DDX58 IFNA1 IFNA2
22 11.89 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IFNG
23 11.84 IFNB1 IFNG IRF7
24 11.67 IFNA2 IFNB1 IFNG
25
Show member pathways
11.57 IFNAR1 IFNAR2 IFNG
26 11.52 IFNAR1 IFNAR2 JAK1
27 11.4 IFNA1 IFNA2 IFNB1
28 11.38 IFNA2 IFNB1 IFNG JAK1
29 10.84 IFNAR1 IFNB1
30
Show member pathways
10.53 DDX58 IFNA2 IFNAR1 IFNAR2 IRF3 IRF7

GO Terms for Hepatitis C

Cellular components related to Hepatitis C according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 GPT IFNA1 IFNA2 IFNB1 IFNG IFNL4
2 bicellular tight junction GO:0005923 9.13 CLDN1 CLDN6 DDX58

Biological processes related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.98 CD81 IFNA2 IFNAR2 IFNB1 IFNG
2 viral process GO:0016032 9.97 CD81 CLDN1 CLDN6 DDX58 IRF3 IRF7
3 adaptive immune response GO:0002250 9.95 IFNA1 IFNA2 IFNB1 IFNG
4 cytokine-mediated signaling pathway GO:0019221 9.95 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
5 interferon-gamma-mediated signaling pathway GO:0060333 9.83 IFNG IRF3 IRF7 JAK1
6 viral entry into host cell GO:0046718 9.83 CD81 CLDN1 CLDN6 LDLR SCARB1
7 B cell differentiation GO:0030183 9.8 IFNA1 IFNA2 IFNB1
8 response to virus GO:0009615 9.8 DDX58 IFNAR1 IFNAR2 IFNB1 IFNG IRF7
9 humoral immune response GO:0006959 9.76 IFNA1 IFNA2 IFNB1 IFNG
10 B cell proliferation GO:0042100 9.75 IFNA1 IFNA2 IFNB1
11 positive regulation of interferon-beta production GO:0032728 9.74 DDX58 IRF3 IRF7
12 T cell activation involved in immune response GO:0002286 9.72 IFNA1 IFNA2 IFNB1
13 natural killer cell activation involved in immune response GO:0002323 9.71 IFNA1 IFNA2 IFNB1
14 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.71 IFNA1 IFNA2 IFNB1 IFNG
15 positive regulation of interferon-alpha production GO:0032727 9.69 DDX58 IRF3 IRF7
16 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.66 CLDN1 CLDN6
17 cellular response to low-density lipoprotein particle stimulus GO:0071404 9.66 CD81 LDLR
18 regulation of type I interferon production GO:0032479 9.65 IRF3 IRF7
19 cellular response to exogenous dsRNA GO:0071360 9.65 DDX58 IFNB1
20 response to exogenous dsRNA GO:0043330 9.65 DDX58 IFNA1 IFNA2 IFNB1 IRF3
21 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.64 IFNG JAK1
22 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.64 IRF3 IRF7
23 positive regulation of triglyceride biosynthetic process GO:0010867 9.63 LDLR SCARB1
24 regulation of type I interferon-mediated signaling pathway GO:0060338 9.63 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
25 negative regulation of T cell differentiation GO:0045581 9.62 IFNA2 IFNB1
26 cholesterol import GO:0070508 9.61 LDLR SCARB1
27 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.61 IFNA2 IFNB1
28 defense response to virus GO:0051607 9.61 DDX58 IFNA1 IFNA2 IFNAR2 IFNB1 IFNG
29 type I interferon biosynthetic process GO:0045351 9.6 IRF3 IRF7
30 MDA-5 signaling pathway GO:0039530 9.59 IRF3 IRF7
31 regulation of phosphatidylcholine catabolic process GO:0010899 9.56 LDLR SCARB1
32 type I interferon signaling pathway GO:0060337 9.23 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IRF3
33 innate immune response GO:0045087 10.04 DDX58 IFNA1 IFNA2 IFNL4 IRF3 IRF7
34 regulation of signaling receptor activity GO:0010469 10.02 IFNA1 IFNA2 IFNB1 IFNG IFNL4

Molecular functions related to Hepatitis C according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 IFNA1 IFNA2 IFNB1 IFNG IFNL4
2 cytokine receptor binding GO:0005126 9.5 IFNA1 IFNA2 IFNB1
3 low-density lipoprotein particle binding GO:0030169 9.37 LDLR SCARB1
4 type I interferon receptor activity GO:0004905 9.26 IFNAR1 IFNAR2
5 type I interferon receptor binding GO:0005132 9.13 IFNA1 IFNA2 IFNB1
6 virus receptor activity GO:0001618 9.02 CD81 CLDN1 CLDN6 LDLR SCARB1

Sources for Hepatitis C

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70